Press release
Advanced Renal Cell Carcinoma Market Expected to rise by 2034, CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics, expected to drive market expansion | DelveInsight
Advanced Renal Cell Carcinoma market 2034
The Advanced Renal Cell Carcinoma market report also offers comprehensive insights into the Advanced Renal Cell Carcinoma market size, share, Advanced Renal Cell Carcinoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Advanced Renal Cell Carcinoma market size growth forward.
Some of the key highlights from the Advanced Renal Cell Carcinoma Market Insights Report:
*
As per DelveInsight analysis, the Advanced Renal Cell Carcinoma market is anticipated to witness growth at a considerable CAGR
*
Several key pharmaceutical companies, including CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics, and others, are developing novel products to improve the Advanced Renal Cell Carcinoma treatment outlook.
*
In July 2024, the US Food and Drug Administration (FDA) granted Fast Track designation to ADI-270, a novel drug for treating patients with metastatic or advanced clear cell renal cell carcinoma (RCC).
*
In July 2024, AVEO Oncology revealed that the TiNivo-2 Phase III clinical trial, which tested nivolumab combined with low-dose FOTIVDA Registered (tivozanib) in patients with advanced metastatic RCC who had previously undergone immune checkpoint inhibitor (ICI) treatment, did not meet its primary goal of improving progression-free survival (PFS).
*
June 2024, Adicet Bio announced that the FDA had cleared its investigational new drug (IND) application for ADI-270, enabling the company to launch a Phase I clinical trial for patients with relapsed/refractory RCC.
*
In June 2024, Telix Pharmaceuticals completed submitting a Biologics License Application (BLA) to the FDA for their radiodiagnostic PET agent, TLX250-CDx, which is used to image clear cell RCC (ccRCC).
*
In June 2024, the FDA approved Adicet Bio's IND application, allowing the start of a Phase I trial for ADI-270 in patients with relapsed or refractory RCC (r/r RCC).
*
According to DelveInsight, the market for advanced renal cell carcinoma (RCC) is projected to experience steady growth at a solid compound annual growth rate (CAGR) by 2034.
*
Leading companies in the advanced RCC market, such as Exelixis, Bristol-Myers Squibb (BMS), AstraZeneca, and HUTCHMED, are pushing forward with the development of new treatments for advanced renal cell carcinoma, demonstrating a strong commitment within the pharmaceutical industry to innovate and improve patient care for this aggressive cancer.
Strategise your business goals by understanding market dynamics @ Advanced Renal Cell Carcinoma Market Landscape [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Advanced Renal Cell Carcinoma Overview
Renal cell carcinoma (RCC) is the most common type of kidney cancer, arising in the small tubules that help filter waste and direct essential substances into the bloodstream. When RCC spreads to other parts of the body, it becomes metastatic renal cell carcinoma (mRCC), also known as stage IV. While the progression rate of mRCC varies, recent advancements in treatment have improved patient outcomes and quality of life.
Common symptoms of RCC include blood in the urine, back pain, weight loss, fatigue, fever, and high blood pressure. As the cancer advances, symptoms like pain, shortness of breath, and weakness may develop, depending on where the cancer spreads.
Do you know the treatment paradigms for different countries? Download our Advanced Renal Cell Carcinoma Market Sample Report [https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Advanced Renal Cell Carcinoma Epidemiology Segmentation
DelveInsight's Advanced Renal Cell Carcinoma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Advanced Renal Cell Carcinoma historical patient pools and forecasted Advanced Renal Cell Carcinoma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Advanced Renal Cell Carcinoma Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
*
Advanced Renal Cell Carcinoma Prevalence
*
Age-Specific Advanced Renal Cell Carcinoma Prevalence
*
Gender-Specific Advanced Renal Cell Carcinoma Prevalence
*
Diagnosed and Treatable Cases of Advanced Renal Cell Carcinoma
Visit for more @ Advanced Renal Cell Carcinoma Epidemiological Insights [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Advanced Renal Cell Carcinoma Market Outlook
Leading companies in the advanced renal cell carcinoma (RCC) space-such as Exelixis, Bristol-Myers Squibb (BMS), AstraZeneca, and HUTCHMED-are actively progressing their key drug candidates through different stages of clinical development. Their focus on innovation and expanding treatment options is fueling a positive market outlook. As these therapies advance, they are expected to greatly improve patient outcomes and address significant unmet needs. The competitive landscape is set to evolve rapidly, driven by breakthroughs in targeted therapies, immunotherapies, and combination approaches aimed at boosting survival rates and enhancing patients' quality of life.
Advanced Renal Cell Carcinoma Marketed Drugs
*
KEYTRUDA (pembrolizumab): Merck
*
WELIREG (belzutifan): Merck
Advanced Renal Cell Carcinoma Emerging Drugs
*
Zanzalintinib (XL092) + Nivolumab: Exelixis/BMS
*
Savolitinib + Durvalumab: AstraZeneca/HUTCHMED
Advanced Renal Cell Carcinoma Key Companies
*
CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics, and others
For more information, visit Advanced Renal Cell Carcinoma Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Scope of the Advanced Renal Cell Carcinoma Market Report:
*
11 Years Forecast
*
7MM Coverage
*
Descriptive overview of Advanced Renal Cell Carcinoma, causes, signs and symptoms, diagnosis, treatment
*
Comprehensive insight into Advanced Renal Cell Carcinoma epidemiology in the 7MM
*
Advanced Renal Cell Carcinoma marketed and emerging therapies
*
Advanced Renal Cell Carcinoma companies
*
Advanced Renal Cell Carcinoma market drivers and barriers
Table of Contents:
1 Advanced Renal Cell Carcinoma Market Key Comprehensive Insights
2 Advanced Renal Cell Carcinoma Market Report Introduction
3 Competitive Intelligence Analysis for Advanced Renal Cell Carcinoma
4 Advanced Renal Cell Carcinoma Market Analysis Overview at a Glance
5 Executive Summary of Advanced Renal Cell Carcinoma
6 Advanced Renal Cell Carcinoma Epidemiology and Market Methodology
7 Advanced Renal Cell Carcinoma Epidemiology and Patient Population
8 Advanced Renal Cell Carcinoma Patient Journey
9 Advanced Renal Cell Carcinoma Treatment Algorithm, Advanced Renal Cell Carcinoma Current Treatment, and Medical Practices
10 Key Endpoints in Advanced Renal Cell Carcinoma Clinical Trials
11 Advanced Renal Cell Carcinoma Marketed Therapies
12 Advanced Renal Cell Carcinoma Emerging Therapies
13 Advanced Renal Cell Carcinoma: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Advanced Renal Cell Carcinoma
16 Advanced Renal Cell Carcinoma Market Key Opinion Leaders Reviews
18 Advanced Renal Cell Carcinoma Market Drivers
19 Advanced Renal Cell Carcinoma Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Advanced Renal Cell Carcinoma Epidemiology 2034
DelveInsight's "Advanced Renal Cell Carcinoma - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Advanced Renal Cell Carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Advanced Renal Cell Carcinoma Pipeline 2024
"Advanced Renal Cell Carcinoma Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Advanced Renal Cell Carcinoma market. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided, which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-renal-cell-carcinoma-market-expected-to-rise-by-2034-coimmune-merck-dohme-xynomic-pharmaceuticals-nikang-therapeutics-expected-to-drive-market-expansion-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Renal Cell Carcinoma Market Expected to rise by 2034, CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics, expected to drive market expansion | DelveInsight here
News-ID: 3991384 • Views: …
More Releases from ABNewswire
Bardet-Biedl Syndrome Pipeline 2025: Pioneering Clinical Developments by 8+ Glob …
DelveInsight's, "Bardet-Biedl Syndrome - Pipeline Insight, 2025," report provides comprehensive insights about 1+ companies and 1+ pipeline drugs in Bardet-Biedl Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Bardet-Biedl Syndrome (BBS) increasingly impacting populations worldwide and contributing…
Brain Metastases Pipeline 2025: Pioneering Clinical Advancements by 40+ Global L …
Brain Metastases companies are Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, and others.
With brain metastases increasingly prevalent worldwide and contributing to comorbid conditions such as diabetes, cardiovascular…
Anaplastic Thyroid Cancer Pipeline 2025: Innovative Clinical Developments by 8+ …
DelveInsight's, "Anaplastic Thyroid Cancer - Pipeline Insight, 2025," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With anaplastic thyroid cancer increasingly prevalent worldwide and…
Cabinets 4 Less Scottsdale Showroom Offers Affordable Cabinetry Solutions
Cabinets 4 Less Scottsdale, a premier cabinet store located at 8445 E. McDonald Dr. in Scottsdale, AZ, is expanding its showroom to offer homeowners, contractors, and designers affordable, high-quality cabinetry. With a wide selection of styles and finishes, personalized consultations, and reliable service, the store provides cost-effective solutions for remodeling and construction projects in Scottsdale's growing housing market.
SCOTTSDALE, AZ - September 30, 2025 - Cabinets 4 Less Scottsdale [https://cabinets4lessscottsdale.com], a…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
